EirGenix Past Earnings Performance
Past criteria checks 0/6
EirGenix has been growing earnings at an average annual rate of 15.2%, while the Life Sciences industry saw earnings growing at 21.9% annually. Revenues have been growing at an average rate of 22.7% per year.
Key information
15.2%
Earnings growth rate
29.7%
EPS growth rate
| Life Sciences Industry Growth | 5.5% |
| Revenue growth rate | 22.7% |
| Return on equity | -9.1% |
| Net Margin | -89.5% |
| Next Earnings Update | 09 May 2024 |
Revenue & Expenses BreakdownBeta
How EirGenix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,023 | -915 | 316 | 952 |
| 30 Sep 23 | 987 | -618 | 295 | 737 |
| 30 Jun 23 | 1,138 | -533 | 289 | 782 |
| 31 Mar 23 | 1,336 | -333 | 273 | 793 |
| 31 Dec 22 | 1,481 | -116 | 287 | 800 |
| 30 Sep 22 | 1,483 | -4 | 277 | 742 |
| 30 Jun 22 | 1,778 | 355 | 259 | 679 |
| 31 Mar 22 | 1,814 | 201 | 296 | 760 |
| 31 Dec 21 | 1,697 | -43 | 258 | 894 |
| 30 Sep 21 | 1,511 | -341 | 245 | 1,115 |
| 30 Jun 21 | 1,247 | -743 | 239 | 1,279 |
| 31 Mar 21 | 1,085 | -923 | 186 | 1,422 |
| 31 Dec 20 | 1,072 | -1,042 | 175 | 1,562 |
| 30 Sep 20 | 991 | -1,029 | 162 | 1,514 |
| 30 Jun 20 | 688 | -1,260 | 153 | 1,478 |
| 31 Mar 20 | 627 | -1,063 | 142 | 1,270 |
| 31 Dec 19 | 476 | -861 | 143 | 960 |
| 30 Sep 19 | 395 | -681 | 141 | 738 |
| 30 Jun 19 | 365 | -475 | 134 | 528 |
| 31 Mar 19 | 288 | -414 | 123 | 408 |
| 31 Dec 18 | 282 | -368 | 112 | 344 |
| 30 Sep 18 | 295 | -304 | 100 | 304 |
| 30 Jun 18 | 330 | -251 | 93 | 286 |
| 31 Mar 18 | 315 | -229 | 91 | 256 |
| 31 Dec 17 | 298 | -175 | 91 | 199 |
| 30 Sep 17 | 281 | -172 | 88 | 188 |
| 30 Jun 17 | 258 | -167 | 86 | 175 |
| 31 Mar 17 | 256 | -140 | 80 | 162 |
| 31 Dec 16 | 253 | -112 | 75 | 150 |
| 30 Sep 16 | 215 | -110 | 73 | 129 |
| 30 Jun 16 | 176 | -107 | 72 | 108 |
| 31 Mar 16 | 140 | -121 | 69 | 104 |
| 31 Dec 15 | 103 | -135 | 67 | 99 |
| 31 Dec 14 | 54 | -133 | 43 | 87 |
| 31 Dec 13 | 9 | -105 | 24 | 41 |
Quality Earnings: 6589 is currently unprofitable.
Growing Profit Margin: 6589 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6589 is unprofitable, but has reduced losses over the past 5 years at a rate of 15.2% per year.
Accelerating Growth: Unable to compare 6589's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6589 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (0.4%).
Return on Equity
High ROE: 6589 has a negative Return on Equity (-9.14%), as it is currently unprofitable.